Risk Assessment Strategy / Tools & Technology

Topic	Replies	Views	Activity
Carcinogenic Potency Database - Access free With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…	3	713	August 22, 2022
About the Risk Assessment Strategy / Tools & Technology category	0	247	April 14, 2021
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day	15	511	September 25, 2023
Nitrosamines risk assessments for Topical herbal extracts Manufacturing	1	120	September 20, 2023
Enhanced Ames Test Conditions for N-nitrosamines (Q&A Rev.16)	9	685	September 13, 2023
Quantitation of Reactive Nitrosating Agents in Pharmaceutical Excipients for N‑Nitrosamine Risk Assessments Excipients	4	568	September 7, 2023
Regulatory Highlights(OPR&D)	13	1106	September 7, 2023
Forced Degradation and the NAP test	3	208	September 2, 2023
N-nitrosoamides - a horse of a different color Drug_Substance_APIs	32	1468	September 1, 2023
QSAR Toolbox - Free software. Any experience?	16	567	August 23, 2023
Potency score for protected hydroxy group	2	276	August 22, 2023
Risk Assessemento of Nitrosamines in soft capsule	6	292	August 16, 2023
On the Risk of Nitrosamine Contamination during blister packaging Packaging	2	297	August 10, 2023
Anybody inquired about Nitrosamines in Poly bags? Packaging	6	476	August 5, 2023
N-Nitroso Betahistine formation	2	138	July 28, 2023
Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies NDSRI	3	377	July 26, 2023
Nitrosamines and bioequivalence studies	4	462	July 20, 2023
Duplex Sequencing - Future of mutagenicity assessment	0	172	July 12, 2023
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals	16	1374	July 3, 2023
Low Nitrite Excipients - it’s happening	2	462	June 30, 2023
Nitrosamine Risk Assessment for Drug Product Manufacturer with 50+ APIs	4	339	May 4, 2023
Instem SOT 2023 Presentation on Assessing N-nitrosamines Potency Classes	1	325	May 2, 2023
A Consideration of the Extent That Tertiary Amines Can Form N-Nitroso Dialkylamines in Pharmaceutical Products NDSRI	1	643	April 25, 2023
NDMA formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product Drug_Substance_APIs	0	467	March 24, 2023
Nitrosamines in topical products	3	459	March 9, 2023
Formation of Dialkyl-N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation NDSRI	6	634	February 25, 2023
Anybody has working with a Gliclazide nitrosamine? Drug_Substance_APIs	3	529	February 14, 2023
IPEC Europe announces the availability of the revised “Questionnaire for Excipient Nitrosamines Risk Evaluation” (Version 4, 2022)	11	661	February 14, 2023
Lhasa Tutorial Vid on new Mirabilis 4.0	2	277	January 31, 2023
What to do with Nitrite content reported by Excipients?	0	421	January 25, 2023

Carcinogenic Potency Database - Access free

With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…